1.
Acta Pharmaceutica Sinica B
;
(6): 1607-1616, 2021.
Article
in English
| WPRIM
| ID: wpr-888823
ABSTRACT
Remdesivir (RDV) is the only US Food and Drug Administration (FDA)-approved drug for treating COVID-19. However, RDV can only be given by intravenous route, and there is a pressing medical need for oral antivirals. Significant evidence suggests that the role of the parent nucleoside GS-441524 in the clinical outcomes of RDV could be largely underestimated. We performed an